Last reviewed · How we verify
Hepalean Heparin
Hepalean is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa.
Hepalean is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa. Used for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.
At a glance
| Generic name | Hepalean Heparin |
|---|---|
| Sponsor | McMaster University |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect target); Factors Xa and IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of coagulation factors. This prevents the formation of thrombin and fibrin, thereby inhibiting clot formation. Hepalean, as an LMWH derivative, offers more predictable pharmacokinetics and longer half-life compared to unfractionated heparin.
Approved indications
- Thromboembolism prophylaxis and treatment
- Deep vein thrombosis prevention and treatment
- Pulmonary embolism prevention and treatment
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Osteoporosis (with long-term use)
Key clinical trials
- Comparison of Heparin Types; Efficacy and Safety (PHASE4)
- Comparative Study of Two Brands of Heparin Already on the Market (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |